CRISPR Therapeutics Stock News

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

Last month, the company's first treatment received clearance from European Union regulators, having previously been approved in the U.S. and the U.K. Its cash burn was lower than expected in the fourt

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.

Samarth Kulkarni, Crispr Therapeutics CEO, joins 'Power Lunch' to discuss the hurdles to getting rare disease drugs through regulation, what consumers can look forward to in gene editing, and much mor

CRISPR Therapeutics is launching its first medicine, which is bullish. It'll also be giving investors updates on a couple of important programs.

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are research

CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.

CRISPR Therapeutics AG NASDAQ: CRSP made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTX received the first-ever FDA approval for a gene-editing therapy for sickle-cel

CRISPR Therapeutics just wowed the market by launching its first drug. Caribou Biosciences is nowhere near an attempt at a launch.

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR

Cathie Wood's biggest bet in her healthcare fund is on a gene editing company. Gene editing has the potential to offer functional cures for serious diseases, so it could be a gamechanger.

Cathie Wood stocks make headlines for their potential to be at the leading edge of disruptive technologies and generate high returns. Yet, Wood's flagship ARK Innovation ETF (NYSEARCA: ARKK ) has dec

CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea